Cellectis S.A. reported full‑year 2025 financial results, with consolidated revenue of $79.6 million, a 62 % increase from $49.2 million in 2024. The company posted a net loss of $67.6 million, a widening from the $36.8 million loss in 2024, and operating cash burn remained high. Cash, cash equivalents, and fixed‑term deposits totaled $211 million as of December 31 2025, giving the company a runway into the second half of 2027.
Revenue growth was driven largely by the partnership with AstraZeneca, which contributed a significant portion of the year‑over‑year increase. In the fourth quarter, Cellectis posted revenue of $17.1 million, beating the consensus estimate of $10.02 million by 70.66 % and supporting the overall 62 % year‑over‑year rise.
The widening net loss was primarily caused by higher operating expenses and a one‑time financial charge. The company’s net financial loss shifted from a gain in 2024 to a loss in 2025, largely due to a decline in financial income and an increase in financial expenses, which offset the revenue gains.
The $211 million cash position provides a solid financial cushion, allowing Cellectis to fund its pivotal Phase 2 program for lasme‑cel and Phase 1 program for eti‑cel through the second half of 2027. The company’s cash equivalents and fixed‑term deposits as of December 31 2025 remain sufficient to support operations into H2 2027.
CEO André Choulika said, “Lasme‑cel demonstrated a potentially transformative efficacy profile in one of oncology’s most challenging settings, achieving 100 % overall response rate in the target Phase 2 population. Critically, lasme‑cel converted all patients in the target population into transplant‑eligible candidates. The pivotal Phase 2 is now enrolling, and with a BLA submission anticipated in 2028, lasme‑cel is on a clear regulatory path to potentially becoming the first off‑the‑shelf CAR‑T therapy to address this high unmet medical need.” CFO Arthur Stril added, “We believe our current cash position gives us the financial runway to execute on our pivotal phase 2 program for lasme‑cel and our phase 1 for eti‑cel, and deliver two key readouts in Q4 2026, the first interim analysis with 40 patients for lasme‑cel and the full phase 1 data set for eti‑cel. We are well positioned financially to execute on these two trials as our cash equivalents and fixed term deposits as of December 31 2025 remain sufficient to fund our operations into H2 2027.”
Management remains confident that the company’s pipeline and partnership strategy will continue to drive growth, while acknowledging the need to manage costs as manufacturing and clinical programs scale.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.